Digital Library
Close Browse articles from a journal
     Journal description
       All volumes of the corresponding journal
         All issues of the corresponding volume
                                       All articles of the corresponding issues
 
                             128 results found
no title author magazine year volume issue page(s) type
1 A clinical, neuropsychological and olfactory evaluation of a large family with LRRK2 mutations Lohmann, Ebba
2009
15 Supplement 2 p. 273-276
4 p.
article
2 Analysis of PArkin Co-Regulated Gene in a Taiwanese–Ethnic Chinese cohort with early-onset Parkinson's disease Taylor, Juliet M.
2009
15 Supplement 2 p. 417-421
5 p.
article
3 Association of a polymorphism in the ABCB1 gene with Parkinson's disease Westerlund, Marie
2009
15 Supplement 2 p. 422-424
3 p.
article
4 A Swedish family with de novo α-synuclein A53T mutation: Evidence for early cortical dysfunction Puschmann, Andreas
2009
15 Supplement 2 p. 627-632
6 p.
article
5 Avances en tratamiento medico de la enfermedad de Parkinson [Advances in the medical treatment of Parkinson's disease] Chaná, Pedro
2009
15 Supplement 2 p. S22-S25
4 p.
article
6 Clinical features of LRRK2 parkinsonism Haugarvoll, Kristoffer
2009
15 Supplement 2 p. S205-S208
4 p.
article
7 Clinimetric analyses of the Modified Parkinson Activity Scale Keus, S.H.J.
2009
15 Supplement 2 p. 263-269
7 p.
article
8 Continuous sleep EEG monitoring in PD patients with and without sleep attacks Möller, Jens Carsten
2009
15 Supplement 2 p. 238-241
4 p.
article
9 Dementia and visual hallucinations associated with limbic pathology in Parkinson's disease Kalaitzakis, M.E.
2009
15 Supplement 2 p. 196-204
9 p.
article
10 Differential regulation of microglial motility by ATP/ADP and adenosine Gyoneva, Stefka
2009
15 Supplement 2 p. S195-S199
5 p.
article
11 Does autophagy worsen or improve the survival of dopaminergic neurons? Pasquali, Livia
2009
15 Supplement 2 p. S24-S27
4 p.
article
12 Does melatonin help save dopaminergic cells in MPTP-treated mice? Ma, Jeannine
2009
15 Supplement 2 p. 307-314
8 p.
article
13 Dopamine receptors and l-dopa-induced dyskinesia Berthet, Amandine
2009
15 Supplement 2 p. S8-S12
5 p.
article
14 Dystonia: a surgeon's perspective Aziz, Tipu Z.
2009
15 Supplement 2 p. S75-S80
6 p.
article
15 Editorial Board 2009
15 Supplement 2 p. i-
1 p.
article
16 Editorial Board 2009
15 Supplement 2 p. i-
1 p.
article
17 Editorial Board 2009
15 Supplement 2 p. i-
1 p.
article
18 Evaluation of gastric emptying in familial and sporadic Parkinson disease Krygowska-Wajs, Anna
2009
15 Supplement 2 p. 692-696
5 p.
article
19 Exercise programs improve mobility and balance in people with Parkinson's disease Gobbi, Lilian T.B.
2009
15 Supplement 2 p. S49-S52
4 p.
article
20 Familial parkinsonism: Study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes Hasegawa, Kazuko
2009
15 Supplement 2 p. 300-306
7 p.
article
21 Genetic factors influencing age at onset in LRRK2-linked Parkinson disease Golub, Yulia
2009
15 Supplement 2 p. 539-541
3 p.
article
22 Genetic screening for LRRK2 gene G2019S mutation in Parkinson's disease patients from Southern Italy De Rosa, Anna
2009
15 Supplement 2 p. 242-244
3 p.
article
23 GIGYF2 mutations are not a frequent cause of familial Parkinson's disease Di Fonzo, Alessio
2009
15 Supplement 2 p. 703-705
3 p.
article
24 Haplotype analysis of Lrrk2 R1441H carriers with parkinsonism Ross, Owen A.
2009
15 Supplement 2 p. 466-467
2 p.
article
25 High intensity eccentric resistance training decreases bradykinesia and improves quality of life in persons with Parkinson's disease: A preliminary study Dibble, Leland E.
2009
15 Supplement 2 p. 752-757
6 p.
article
26 Integration deficiencies associated with continuous limb movement sequences in Parkinson's disease Park, Jin-Hoon
2009
15 Supplement 2 p. 682-687
6 p.
article
27 Intrafamilial variability of Parkinson phenotype in SCAs: Novel cases due to SCA2 and SCA3 expansions Socal, M.P.
2009
15 Supplement 2 p. 374-378
5 p.
article
28 Learning and consolidation of visuo-motor adaptation in Parkinson's disease Marinelli, Lucio
2009
15 Supplement 2 p. 6-11
6 p.
article
29 Long half-life and prolonged-release dopamine receptor agonists: a review of ropinirole prolonged-release studies Onofrj, M.
2009
15 Supplement 2 p. S85-S92
8 p.
article
30 LRRK2 gene G2019S mutation and SNPs [haplotypes] in subtypes of Parkinson's disease Patra, Biswanath
2009
15 Supplement 2 p. 175-180
6 p.
article
31 LRRK2 mutations in patients with Parkinson's disease from Peru and Uruguay Mata, Ignacio F.
2009
15 Supplement 2 p. 370-373
4 p.
article
32 Mechanism and treatment of dropped head syndrome associated with parkinsonism Oyama, Genko
2009
15 Supplement 2 p. 181-186
6 p.
article
33 Neuropathology of non-motor features of Parkinson disease Dickson, Dennis W.
2009
15 Supplement 2 p. S1-S5
5 p.
article
34 Neuroprotective and toxic changes in microglia in neurodegenerative disease Sawada, Makoto
2009
15 Supplement 2 p. S39-S41
3 p.
article
35 New considerations in the medical management of early Parkinson's disease: Impact of recent clinical trials on treatment strategy Hauser, Robert A.
2009
15 Supplement 2 p. S17-S21
5 p.
article
36 Non-motor symptoms in a prevalent population with Parkinson's disease in Tanzania Dotchin, C.L.
2009
15 Supplement 2 p. 457-460
4 p.
article
37 O.024 Advances in the medical treatment of Parkinson's disease Chana, P.
2009
15 Supplement 2 p. S7-
1 p.
article
38 O.075 Atypical parkinsonism Lang, A.E.
2009
15 Supplement 2 p. S19-
1 p.
article
39 Octarepeat changes of prion protein in Parkinson's disease Wang, Vinchi
2009
15 Supplement 2 p. 53-58
6 p.
article
40 O.027 Dealing with the devil in the detail - some thoughts about the next model of the basal ganglia Arbuthnott, G.
2009
15 Supplement 2 p. S8-
1 p.
article
41 O.072 Dystonia Schneider, S.
2009
15 Supplement 2 p. S19-
1 p.
article
42 O.010 Emergencies in PD Pal, P.
2009
15 Supplement 2 p. S3-S4
2 p.
article
43 O.041 From bench to bedside: new treatments for Friedreich's ataxia Pandolfo, M.
2009
15 Supplement 2 p. S11-
1 p.
article
44 O.085 Huntington disease (HD): clinical features and experimental therapeutics Shoulson, I.
2009
15 Supplement 2 p. S22-
1 p.
article
45 O.080 Leucine-rich repeat kinase 2: animal models Farrer, M.
2009
15 Supplement 2 p. S21-
1 p.
article
46 O.099 Low frequency stimulation of PPTg in PD: minor beneflts on gait, peculiar changes of cortical metabolism and cognitive performance Stefani, A.
2009
15 Supplement 2 p. S26-
1 p.
article
47 Opening velocity, a novel parameter, for finger tapping test in patients with Parkinson's disease Yokoe, M.
2009
15 Supplement 2 p. 440-444
5 p.
article
48 Osteoporosis in Parkinson's disease Invernizzi, Marco
2009
15 Supplement 2 p. 339-346
8 p.
article
49 O.058 Will continuous dopamine stimulation prevent motor complications? Antonini, A.
2009
15 Supplement 2 p. S15-
1 p.
article
50 P3.042 A GATA-2-switch model of a-synuclein overexpression in sporadic Parkinson's disease Liao, Z.
2009
15 Supplement 2 p. S159-
1 p.
article
51 P3.156 Alcohol dehydrogenase 2 polymorphism is not associated to the risk for essential tremor Martinez-Oliva, C.
2009
15 Supplement 2 p. S188-
1 p.
article
52 P2.058 Anatomical localization of active contacts of deep brain electrodes – technical note Urgosik, D.
2009
15 Supplement 2 p. S104-
1 p.
article
53 P2.092 A randomized, double-blind evaluation of levodopa/carbidopa/entacapone versus immediate-release levodopa/carbidopa in patients with Parkinson's disease exhibiting nonmotor symptoms of wearing off Stacy, M.
2009
15 Supplement 2 p. S113-S114
2 p.
article
54 PARK11 gene (GIGYF2) variants Asn56Ser and Asn457Thr are not pathogenic for Parkinson's disease Zimprich, Alexander
2009
15 Supplement 2 p. 532-534
3 p.
article
55 P2.106 Assessment of symptomatic and neuroprotective efflcacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease Pinna, A.
2009
15 Supplement 2 p. S117-
1 p.
article
56 P1.174 A successful computer method for assessing drawing impairment in Parkinson's disease Westin, J.
2009
15 Supplement 2 p. S73-S74
2 p.
article
57 P1.184 Behavioral disturbances in Parkinson's disease: a study from Slovak movement disorders center Martinková, J.
2009
15 Supplement 2 p. S76-
1 p.
article
58 P2.017 Behavioural and biochemical characterization of c-Rel mutant mice as model of Parkinson's disease Pinna, A.
2009
15 Supplement 2 p. S92-
1 p.
article
59 P1.071 Botulinum toxin type A in the treatment of lower-limb spasticity in children with cerebral palsy Teive, H.
2009
15 Supplement 2 p. S47-
1 p.
article
60 P3.119 Characteristics of resting-state oscillatory activity in the basal ganglia-cortical loop in the 6-OHDA-lesioned rat models of Parkinson's disease Li, M.
2009
15 Supplement 2 p. S178-S179
2 p.
article
61 P3.146 Clinical and MRI correlations in Parkinson's disease patients with headache Verulashvili, I.
2009
15 Supplement 2 p. S185-S186
2 p.
article
62 P3.016 Cognitive features are more predictive of corticobasal degeneration (CBD) pathology than motor features in corticobasal syndrome Kranick, S.
2009
15 Supplement 2 p. S152-
1 p.
article
63 P2.195 Color vision and Parkinson's disease; comparison with essential tremor and controls Kim, J.-S.
2009
15 Supplement 2 p. S142-
1 p.
article
64 P3.160 Communication circles – a cost effective model of on-going speech therapy for individuals with Parkinson's disease Bereskin, B.
2009
15 Supplement 2 p. S189-
1 p.
article
65 P3.082 Covalent modiflcation of superoxide dismutase 2 by dopamine oxidation products Belluzzi, E.
2009
15 Supplement 2 p. S169-
1 p.
article
66 P1.126 Developing a risk model for Parkinson disease Chung, R.-H.
2009
15 Supplement 2 p. S61-
1 p.
article
67 P1.023 Development of task switching and error monitoring in children Gupta, R.
2009
15 Supplement 2 p. S34-S35
2 p.
article
68 P1.054 Effectiveness of learning based training memory and sensorimotor training for patients with focal hand dystonia McKenzie, A.
2009
15 Supplement 2 p. S42-S43
2 p.
article
69 P3.054 Effect of prenatal manganese intoxication on dopaminergic neurotranssmision in the brain of rats lesioned as neonates with 6-hydroxydopamine Nowak, P.
2009
15 Supplement 2 p. S162-
1 p.
article
70 P1.081 Effects of auditory, attentional, and combined cueing strategies on gait during single and dual cognitive tasks in Parkinson's disease Lohnes, C.A.
2009
15 Supplement 2 p. S49-S50
2 p.
article
71 P1.129 End of life in Parkinson's disease Feve, A.
2009
15 Supplement 2 p. S62-
1 p.
article
72 Performance on an Alzheimer-selective odor identification test in patients with Parkinson's disease and its relationship with cerebral dopamine transporter activity Chou, Kelvin L.
2009
15 Supplement 2 p. 640-643
4 p.
article
73 P1.040 Executive and memory decline in a longitudinally followed group of non-demented patients with idiopathic Parkinson's disease Zhelev, Y.
2009
15 Supplement 2 p. S39-
1 p.
article
74 P3.143 Ferroportin1 but not hephaestin was involved in the 6-hydroxydopamine induced iron accumulation in primary ventral mesencephalic neurons and MES23.5 cells Song, N.
2009
15 Supplement 2 p. S185-
1 p.
article
75 P3.030 GBA mutations and Parkinson disease in Italian population D'Angelo, R.
2009
15 Supplement 2 p. S155-S156
2 p.
article
76 Photophobia, visual hallucinations, and REM sleep behavior disorder in progressive supranuclear palsy and corticobasal degeneration: A prospective study Cooper, Alex D.
2009
15 Supplement 2 p. 59-61
3 p.
article
77 P1.143 How important is unrelated co-morbidity in Parkinson's disease? Leckie, K.
2009
15 Supplement 2 p. S65-
1 p.
article
78 P1.215 Indian variant PSP-P: clinical and quantitative MRI proflle Nehru, R.
2009
15 Supplement 2 p. S84-
1 p.
article
79 P2.034 Intraoperative stereotactic accuracy of the FHC microTargeting and Axon Instruments microdrives compared Ahmed, S.
2009
15 Supplement 2 p. S97-
1 p.
article
80 P1.110 123I-/V-cu-fluoro-propyl-2β-carbomethoxy-3β-(4-iodophenyl) nortropane ([123I] FP-CIT) SPECT in cases of multiple system atrophy Gontu, V.
2009
15 Supplement 2 p. S57-
1 p.
article
81 Plastic effects of L-DOPA treatment in the basal ganglia and their relevance to the development of dyskinesia Cenci, M. Angela
2009
15 Supplement 2 p. S59-S63
5 p.
article
82 P3.174 Laughing during sleep as a manifestation of rapid eye movement sleep behaviour disorder Siclari, F.
2009
15 Supplement 2 p. S193-
1 p.
article
83 P2.020 Lipopolysaccharide rat model for Parkinson's disease neurodegeneration: disease-associated proteins, cytokines and inflammatory cells in brain tissue Schiess, M.
2009
15 Supplement 2 p. S93-
1 p.
article
84 P3.191 LRRK2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications Qing, H.
2009
15 Supplement 2 p. S197-
1 p.
article
85 P2.140 Meta-analysis of DBS surgery in patients with advanced Parkinson's disease Ives, N.
2009
15 Supplement 2 p. S127-
1 p.
article
86 P1.098 Microstructural integrity of white matter in patients with Parkinson's disease (PD): diffusion tensor imaging and MR-tractography study Rozhkova, Z.
2009
15 Supplement 2 p. S54-
1 p.
article
87 P3.102 Mitochondrial defects induced by a loss of fusion effect in mutant PINK1 can be rescued through the flssion/fusion pathway Cui, M.
2009
15 Supplement 2 p. S174-
1 p.
article
88 P1.006 Neurochemical and neuroplastic changes in chronic methyphenidate administered brains Sadasivan, S.
2009
15 Supplement 2 p. S30-
1 p.
article
89 P3.088 Nicotinamide dosage regulates redox [NAD(H)] and is relevant to pellagra, brain development and diseases of ageing including dementia and parkinsonism Williams, A.C.
2009
15 Supplement 2 p. S171-
1 p.
article
90 P3.065 Nimesulide, a preferential cyclooxygenase-2 inhibitor exhibits neuroprotection against MPTP-induced striatal lesions in rats: behavioral, biochemical, cellular and histological evidences Gupta, A.
2009
15 Supplement 2 p. S165-
1 p.
article
91 P3.040 Non synonymous GIGYF2 variants in Parkinson's disease Prakash, K.M.
2009
15 Supplement 2 p. S158-
1 p.
article
92 P3.085 Novel bio-panning technique to isolate scFv against low concentrations of toxic natural brain derived Abeta oligomers Kasturirangan, S.
2009
15 Supplement 2 p. S170-
1 p.
article
93 P2.109 Piclozotan reduces dyskinesia and OFF time in Parkinson's disease (PD) patients with L-dopa induced motor complications Hauser, R.A.
2009
15 Supplement 2 p. S118-
1 p.
article
94 P3.039 Polymorphisms in the transcription factor gene GATA2 and GATA-2 target region in a-synuclein (SNCA) are associated with Parkinson's disease (PD) Kay, D.
2009
15 Supplement 2 p. S158-
1 p.
article
95 P1.103 Predictors of impulse control disorders in MMPI-2 in patients suffering from Parkinson's disease: a pilot study Farnikova, K.
2009
15 Supplement 2 p. S55-
1 p.
article
96 P3.071 Protonopathies: deflciency or excess of proton providers and carriers (glucose and nicotinamide) may overwhelm NAD recycling and “short circuit” defenses Williams, A.C.
2009
15 Supplement 2 p. S166-S167
2 p.
article
97 P2.178 Quality of life in patient with Parkinson's disease in Russia Guekht, A.
2009
15 Supplement 2 p. S138-
1 p.
article
98 P3.133 Regulation of movement energetic costs is impaired in basal ganglia disorders Moisello, C.
2009
15 Supplement 2 p. S182-
1 p.
article
99 P3.181 Restless Arms syndrome: report of 2 cases Munhoz, R.P.
2009
15 Supplement 2 p. S194-
1 p.
article
100 P2.123 Ropinirole prolonged release improves nocturnal symptoms in patients with advanced Parkinson's disease: an analysis of grouped items on the PDSS Chaudhuri, K.R.
2009
15 Supplement 2 p. S122-S123
2 p.
article
101 P2.150 Ropinirole prolonged release improves nocturnal symptoms in patients with advanced Parkinson's disease: an analysis of individual items on the PDSS Ondo, W.
2009
15 Supplement 2 p. S130-
1 p.
article
102 P2.164 Ropinirole prolonged release maintains an increase in daily awake time spent “on” in patients with advanced Parkinson's disease Stocchi, F.
2009
15 Supplement 2 p. S134-
1 p.
article
103 Pros and cons of apomorphine and l-dopa continuous infusion in advanced Parkinson's disease Antonini, Angelo
2009
15 Supplement 2 p. S97-S100
4 p.
article
104 P1.218 Safety, tolerability and pharmacokinetics of Cogane™ (PYM50028) studied over 28 days in healthy subjects and patients with mild-moderate Parkinson's disease Priestley, A.
2009
15 Supplement 2 p. S85-
1 p.
article
105 P2.048 Screening and selection process for deep brain stimulation: the Emory experience Revuelta, G.J.
2009
15 Supplement 2 p. S101-
1 p.
article
106 P2.003 Selective spatial learning impairments and attention deflcits precede a frank motor phenotype in a mouse model of Parkinson's disease Browne, S.E.
2009
15 Supplement 2 p. S89-
1 p.
article
107 P1.157 Sensitivity to change of quality of life rating scales used in the PD MED trial Patel, S.
2009
15 Supplement 2 p. S69-
1 p.
article
108 P1.160 Signifacance of asymmetrical onset of symptoms in Parkinson's disease Pokharel, D.
2009
15 Supplement 2 p. S70-
1 p.
article
109 P3.013 Sirtuin inhibitors rescue synuclein toxicity: the natural inhibitor cicotinamide cured parkinsonism in pellagrins yet may be a Jekyll and Hyde Williams, A.C.
2009
15 Supplement 2 p. S151-
1 p.
article
110 P3.177 Sleep-related falling out of bed (SFOB) in Parkinson's disease. A descriptive analysis Carvalho, D.
2009
15 Supplement 2 p. S193-S194
2 p.
article
111 P2.137 Somatodendritic serotonin-1A receptor responsiveness in the attenuation of apomorphine-induced sensitization by buspirone Ikram, H.
2009
15 Supplement 2 p. S126-
1 p.
article
112 P1.095 Spinocerebellar ataxia 3 presenting as Parkinson disease – case series Mendonça, N.
2009
15 Supplement 2 p. S53-
1 p.
article
113 P2.075 Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, protects dopaminergic neurons from neurotoxin-induced damage Wu, H.-M.
2009
15 Supplement 2 p. S109-
1 p.
article
114 P1.112 Symmetric Parkinson's disease and atypical degenerative parkinsonism: common and differential aspects Moscovich, M.
2009
15 Supplement 2 p. S57-S58
2 p.
article
115 P3.034 The analysis of LRRK 2 and parkin gene mutations in Slovakia Kracunova, K.
2009
15 Supplement 2 p. S156-S157
2 p.
article
116 P2.212 The impact of postural alterations and falls in the quality of life in patients with Parkinson's disease Maki, T.
2009
15 Supplement 2 p. S147-
1 p.
article
117 P1.037 The importance of oxidative stress in dementia progression Padurariu, M.
2009
15 Supplement 2 p. S38-
1 p.
article
118 P3.057 The roles of iron, Mn, zinc on the PD development? Relationship between food intake and serum concentrations Tan, X.
2009
15 Supplement 2 p. S163-
1 p.
article
119 P1.009 The utilization of a caregiver questionnaire in an outpatient movement disorder clinic to examine and address caregiver distress Book, E.
2009
15 Supplement 2 p. S31-
1 p.
article
120 P2.061 The value of MRI in the early disease stages of parkinsonian disorders: a prospective three year follow-up study Abdo, W.
2009
15 Supplement 2 p. S105-
1 p.
article
121 P2.181 Time geography and quality of life for persons with Parkinson's disease Mcnulty, T.
2009
15 Supplement 2 p. S139-
1 p.
article
122 P1.201 Wilson disease in young adolescent with hepatitis C – case report Boshkovski, B.
2009
15 Supplement 2 p. S80-S81
2 p.
article
123 Reevaluation of levodopa therapy for the treatment of advanced Parkinson's disease Yokochi, Masayuki
2009
15 Supplement 2 p. S25-S30
6 p.
article
124 Serum inflammatory biomarkers in Parkinson's disease Dufek, M.
2009
15 Supplement 2 p. 318-320
3 p.
article
125 The prognosis of fixed dystonia: A follow-up study Ibrahim, N.M.
2009
15 Supplement 2 p. 592-597
6 p.
article
126 Transdermal delivery of dopamine receptor agonists Reichmann, Heinz
2009
15 Supplement 2 p. S93-S96
4 p.
article
127 Treatment of dysautonomia associated with Parkinson's disease Mostile, Giovanni
2009
15 Supplement 2 p. S224-S232
9 p.
article
128 Triggering endogenous neuroprotective processes through exercise in models of dopamine deficiency Zigmond, Michael J.
2009
15 Supplement 2 p. S42-S45
4 p.
article
                             128 results found
 
 Koninklijke Bibliotheek - National Library of the Netherlands